Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1938 1
1947 2
1949 1
1956 2
1957 2
1959 1
1960 3
1961 5
1962 3
1963 2
1964 1
1965 3
1967 3
1968 1
1970 3
1971 1
1972 2
1973 2
1974 1
1975 4
1977 2
1978 2
1979 1
1980 4
1981 2
1982 3
1983 1
1984 1
1985 4
1986 3
1987 3
1988 2
1989 7
1990 11
1991 5
1992 4
1993 3
1994 5
1995 5
1996 1
1997 2
1999 3
2000 3
2001 1
2002 2
2004 2
2005 4
2006 3
2007 6
2008 2
2009 2
2010 3
2011 1
2012 2
2013 6
2014 6
2015 10
2016 8
2017 6
2018 2
2019 2
2020 1
2021 12
2022 10
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Results by year

Filters applied: . Clear all
Page 1
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.
Lightcap ES, Yu P, Grossman S, Song K, Khattar M, Xega K, He X, Gavin JM, Imaichi H, Garnsey JJ, Koenig E, Zhang H, Lu Z, Shah P, Fu Y, Milhollen MA, Hatton BA, Riceberg J, Shinde V, Li C, Minissale J, Yang X, England D, Klinghoffer RA, Langston S, Galvin K, Shapiro G, Pulukuri SM, Fuchs SY, Huszar D. Lightcap ES, et al. Among authors: koenig e. Sci Transl Med. 2021 Sep 15;13(611):eaba7791. doi: 10.1126/scitranslmed.aba7791. Epub 2021 Sep 15. Sci Transl Med. 2021. PMID: 34524860 Free PMC article.
Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial.
McDonald CM, Shieh PB, Abdel-Hamid HZ, Connolly AM, Ciafaloni E, Wagner KR, Goemans N, Mercuri E, Khan N, Koenig E, Malhotra J, Zhang W, Han B, Mendell JR; the Italian DMD Telethon Registry Study Group, Leuven NMRC Registry Investigators, CINRG Duchenne Natural History Investigators, and PROMOVI Trial Clinical Investigators. McDonald CM, et al. Among authors: koenig e. J Neuromuscul Dis. 2021;8(6):989-1001. doi: 10.3233/JND-210643. J Neuromuscul Dis. 2021. PMID: 34120909 Free PMC article. Clinical Trial.
Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial.
Servais L, Mercuri E, Straub V, Guglieri M, Seferian AM, Scoto M, Leone D, Koenig E, Khan N, Dugar A, Wang X, Han B, Wang D, Muntoni F; SKIP-NMD Study Group. Servais L, et al. Among authors: koenig e. Nucleic Acid Ther. 2022 Feb;32(1):29-39. doi: 10.1089/nat.2021.0043. Epub 2021 Nov 17. Nucleic Acid Ther. 2022. PMID: 34788571 Free PMC article. Clinical Trial.
Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial.
Wagner KR, Kuntz NL, Koenig E, East L, Upadhyay S, Han B, Shieh PB. Wagner KR, et al. Among authors: koenig e. Muscle Nerve. 2021 Sep;64(3):285-292. doi: 10.1002/mus.27347. Epub 2021 Jun 29. Muscle Nerve. 2021. PMID: 34105177 Free PMC article. Clinical Trial.
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
Gupta SK, Berhe M, Crofoot G, Benson P, Ramgopal M, Sims J, McDonald C, Ruane P, Sanchez WE, Scribner A, Liu SY, VanderVeen LA, Dvory-Sobol H, Rhee MS, Baeten JM, Koenig E. Gupta SK, et al. Among authors: koenig e. Lancet HIV. 2023 Jan;10(1):e15-e23. doi: 10.1016/S2352-3018(22)00291-0. Lancet HIV. 2023. PMID: 36566079 Clinical Trial.
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J, White K, SenGupta D, Cheng A, Quirk E. Sax PE, et al. Among authors: koenig e. Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867499 Clinical Trial.
RNA trafficking in axons.
Sotelo-Silveira JR, Calliari A, Kun A, Koenig E, Sotelo JR. Sotelo-Silveira JR, et al. Among authors: koenig e. Traffic. 2006 May;7(5):508-15. doi: 10.1111/j.1600-0854.2006.00405.x. Traffic. 2006. PMID: 16643274 Free article. Review.
[On yeast aldolase].
OHLMEYER P, KOENIG E. OHLMEYER P, et al. Among authors: koenig e. Hoppe Seylers Z Physiol Chem. 1961 Jun 21;324:197-205. doi: 10.1515/bchm2.1961.324.1.197. Hoppe Seylers Z Physiol Chem. 1961. PMID: 13730503 German. No abstract available.
Interferon: a review.
Koenig EL. Koenig EL. Del Med J. 1970 Jan;42(1):4-8. Del Med J. 1970. PMID: 4903695 Review. No abstract available.
European core curriculum in neurorehabilitation.
Sandrini G, Binder H, Hömberg V, Saltuari L, Tarkka I, Smania N, Corradini C, Giustini A, Kätterer C, Picari L, Diserens K, Koenig E, Geurts A, Anghelescu A, Opara J, Tonin P, Kwakkel G, Golyk V, Onose G, Pérennou D, Picelli A. Sandrini G, et al. Among authors: koenig e. Funct Neurol. 2017 Apr/Jun;32(2):63-68. doi: 10.11138/fneur/2017.32.2.063. Funct Neurol. 2017. PMID: 28676138 Free PMC article.
198 results